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Oesophageal s��amo�s cell carcinoma �E�����     
remains a devastating disease �eca�se it is �s�ally not 
detected �ntil it has progressed to an advanced stage. 
Modern imaging techni��es are powerf�l tools in the 
detection�� diagnosis�� and staging of this disease. Early 
detection remains the el�sive ��t essential goal of 
research. Only s�rgical resection at a very early stage 
has �een shown to improve s�rvival rates in patients 
with this disease [�]. 
The prognosis of patients with oesophageal t�mors 
is poor�� and el�cidation of the molec�lar mechanisms 
of t�mor growth and the esta�lishment of informative 
�iomarkers are th�s �nder intensive investigation.
Interle�kin-�� �IL-���� is a pleiotropic cytokine pro-
d�ced mainly �y monocytes and nat�ral killer �NK�� cells�� 
dendritic cells�� Langerhans cells�� keratinocytes and 
K�pffer cells. This interle�kin stim�lates Th� lympho-
cytes development�� proliferation and cytokine prod�c-
tion. It has �een shown to activate cytotoxicity in inflam-
matory diseases and against development many kinds 
of malignant t�mo�rs. The effect of IL-�� on t�mors is 
mediated �y NK cells�� helper cells�� cytotoxic T cells and is 
associated with interferon-γ �IFN-γ�� prod�ction [��4]. 
Interle�kin-�� �IL-������ called interferon-γ-ind�cing 
factor�� is a recently discovered cytokine that ind�ces 
IFN-γ prod�ction in T cells and NK cells. It is synthesized 
�y activated macrophages�� K�pffer cells�� dendritic 
cells�� Langerhans cells and intestinal epithelial cells. 
IL-�� ind�ces proliferation of activated T cells�� activation 
of NK cells�� secretion several cytokines and chemokines 
and participate in innate and ac��ired imm�nity [��� 5�� 
��]. An IL-�� receptor is present in nat�ral killer cells and 
is ind�ced �y IL-��. Th�s�� IL-�� plays an important role 
in cooperation with IL-���� especially in Th� response 
in anticancer imm�nity. At the t�mor site�� locally de-
creased IFN-γ prod�ction after decreased or a�olished 
IL-�� prod�ction was correlated with an �nfavo�ra�le 
o�tcome for patients with colon carcinoma [���� 7]. 
The role of IL-�� and IL-�� in activation of imm�ne 
responses was o�served in oesophageal [�]�� gastric 
[��� ��] and colon [���� 7] cancers. N�mero�s st�dies 
have demonstrated IL-�� and IL-�� a�ility to s�ppress 
t�mor angiogenesis and growth [�����].     
The c�rrent st�dy is the first to testing ser�m IL-�� 
and IL-�� levels in patients with oesophageal s��a-
mo�s cell carcinoma �E�����. The aim of this st�dy was 
to determine�� whether ser�m IL-�� and IL-�� levels can 
�e �sed as diagnostic markers in E��� patients.
Materials and Methods
Forty one patients with oesophageal s��amo�s cell       
carcinoma were investigated �etween ���4 and ���5 in 
the �epartment of Gastrointestinal and General ��rgery�� 
Wrocław Medical �niversity�� �oland. The gro�p com-      
prised 5 women and ��� men aged 44���� years �mean 
age 5� ± � years��. �eripheral �lood was o�tained preope-
ratively from �� consec�tive patients who �nderwent 
s�rgical resection of oesophag�s and from �� patients 
who were treated �y palliative proced�res. The clinical 
stage was assigned according to the sixth edition of the 
TNM classification of the International �nion Against 
�ancer ��I���� [�4]. �ancer gro�p incl�ded: �7 patients 
with stage II�� �� patients with stage III and �� patients with 
stage IV; �7 cases of T��� �� cases of T� and 5 cases of T4; 
� cases of N��� �7 cases of N� and �5 cases of N� + N�; 
�7 cases of M��� � cases of M� and 5 cases of M�. �ontrol 
gro�p consisted of �5 healthy �lood donors: 4 female 
and �� male�� mean age 4� ± �� years.
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Blood samples were taken into sterile vac��m 
t��es and centrif�ged at ���� rpm for �� min. �er�m 
was stored at ��� °� �ntil �se. IL-�� and IL-�� levels 
were determined �y enzyme-linked imm�nosor�ent 
assay �ELI�A�� �Bender Med�ystem�� Vienna�� A�stria��. 
The ELI�A kits meas�red protein levels �sing anti�ody 
p4� and p7� specific for IL-���� and anti-h�man IL-�� 
monoclonal anti�odies. The samples were prepared 
and tested in d�plicate according to the instr�ctions. 
The minim�m detecta�le dose of IL-�� was < �5 pg/ml�� 
and the �pper limit of linearity was ���� pg/ml. The 
minim�m detecta�le dose of IL-�� was < ��.5 pg/ml�� 
and the �pper limit of linearity was 5��� pg/ml.
�ata were expressed as mean ± ���� median and 
range. Analysis of distri��tion of data was carried 
on with �hapiro — Wilk normality test. �ontin�o�s 
varia�les were compared �sing Mann — Whitney � 
test and correlation coefficient was meas�red �sing 
R-�pearman test. �tatistical significance was conside-
red for p < �.�5 and p < �.���.
�t�dies were approved �y Ethics �ommittee �ni-
versity of Medicine in Wrocław�� �oland.
results
Medians of ser�m IL-�� and IL-�� concentrations 
were significantly higher in E��� patients than in the 
healthy s��jects �p < �.����� �Ta�le ���. �er�m IL-��  
and IL-�� levels were significantly higher in s�rgically 
treated patients and in palliative treated patients in 
comparison with control gro�p �p < �.����� �see Ta-
�le ���. �ifferences �etween val�es of IL-�� concen-     
trations in operated and non-operated patients were 
statistically significant �p < �.�5��. 
Table 1. Concentration of ser�m IL-12 and IL-18 in patients with s��amo�s 
cell carcinoma of oesopha��s in comparison with healthy individ�als 
IL-12 (p�/ml) IL-18 (p�/ml)
Mean ± SD Median (ran�e) Mean ± SD Median (ran�e)
Control �ro�p 
(n = 16)
63.7 ± 23.6 63.4  
(29.9–118.0)
48.3 ± 16.4 49.0  
(21.7–74.0)
ESCC patients 
(n = 41)
194.5 ± 
102.7
166,7a  
(76.3 – 561.4)
195.0 ± 
108.4
205.0a  
(28.6–377.0)
– oesopha�ec-
tomy (n = 23)
171.6 ± 
50.6
166,7a  
(91.3–282.1)
155.2 ± 
107.4
146.0a  
(28.6–377.0)
– palliative pro-
ced�re (n = 18)
218.6 ± 
135.7
177.2a  
(76.3–561.4)
237.1 ± 
94.9
239.95a, b  
(38.6–360.0)
ap < 0.001 vs control �ro�p; bp < 0.05 vs oesopha�ectomy �ro�p.
�orrelation of ser�m IL-�� and IL-�� levels with 
t�mor feat�res are presented in Ta�le �. �ignificant 
differences were not o�served �etween ser�m IL-�� 
and ser�m IL-�� levels and patient’s age and sex. 
Medians of IL-�� levels were higher sim�ltaneo�sly 
with the increase in the degree of the development of 
cancer and were statistically significant �etween II and 
IV stage. As the depth of t�mor invasion progressed�� 
ser�m IL-�� and IL-�� amo�nts tended to increase 
and there were significant differences of IL-�� levels 
�etween T� and T� or T� and T4 gro�ps. �er�m IL-�� 
level was significantly elevated �N� vs N�+N��� when 
metastatic regional lymph nodes were present.
�er�m IL-�� and IL-�� levels increased in the pre-
sence of distant metastasis�� in case of IL-�� it was near 
to statistical significance.
Table 2. Ser�m IL-12 and IL-18 levels with respect to clinical and patho-
lo�ical characteristics of oesopha�eal s��amo�s cell carcinoma
Median IL-12 (p�/ml) Median IL-18 (p�/ml)
A�e:
 < 60 years
 > 60 years
163.55
176.20
p = 0.393 204.75
205.0
p = 0.490
Sex:
 Female
 Male
165.00
171.45
p = 0.293 99.00
212.00
p = 0.089
Sta�e:
 II
 III
 IV
176.20
154.20
177.15
II vs III: p = 0.244
II vs IV: p = 0.124
III vs IV: p = 0.060
131.00
199.75
239.95
II vs III: p = 0.186
II vs IV: p = 0.003*
III vs IV: p = 0.250
T�mor depth (T):
 T2
 T3
 T4
166.85
162.70
315.50
T2 vs T3: p = 0.399
T2 vs T4: p = 0.094
T3 vs T4: p = 0.104
105.50
257.70
191.50
T2 vs T3: p = 0.002*
T2 vs T4: p = 0.046*
T3 vs T4: p = 0.212
Re�ional 
lymph nodes 
(N):
 N0
 N1
 
N2 + N3
163.75
157.50
207.75
N0 vs N1: p = 0.497
N0 vs N2 + N3: 
p = 0.061
N1 vs N2 + 
N3: p = 0.057
161,25
151.10
227.30
N0 vs N1: p = 0.210
N0 vs N2 + N3: 
p = 0.040*
N1 vs N2 + N3: 
p = 0.169
Distant me-
tastasis (M):
 M0
 M1
 M2
157.50
165.00
315.50
M0 vs M1: p = 0.306
M0 vs M2: p = 0.053
M1 vs M2: p = 0.054
151.10
267.00
218.00
M0 vs M1: p = 0.112
M0 vs M2: p = 0.108
M1 vs M2: p = 0.449
*Statistical si�nificance for p < 0.05; statistical analysis by Mann �� Whit-
ney U test.
The correlation coefficient for ser�m IL-�� and 
IL-�� levels was not statistically significant.
discussion
IL-�� and IL-�� have �een fo�nd to act synergisti-
cally in their antit�mor activity [��� �5�� ���]. In the c�rrent 
st�dy we tested ser�m IL-�� and IL-�� concentrations 
in �lood of the patients with E����� where ser�m IL-�� 
and IL-�� levels were significantly higher in comparison 
with healthy s��jects. We showed that E��� patients 
s�rgically treated �stage II and III�� had lower amo�nts 
of IL-�� and IL-�� than those in palliative treated pa-
tients �stage IV��. O�r investigations are in agreement 
with st�dy of Ts��oi et al. [�]�� who demonstrated that 
ser�m IL-�� and IL-�� levels in patients with oesopha-
geal carcinoma were significantly higher than in control 
gro�p. These res�lts s�ggest that IL-�� and IL-�� 
mediate the innate and adaptive antit�mor imm�ne 
response. It is �elieved that effects of IL-�� and IL-�� 
on t�mors are mediated �y nat�ral killer cells�� helper 
cells and cytotoxic T cells in association with IFN- γ 
prod�ction [��� 7�� ��� ���]. �ome a�thors reported that 
cancer imm�notherapy with IL-�� res�lts in eradication 
of disseminated disease in patients with colon cancer�� 
malignant mesothelioma or l�ng cancer [�7���]. 
It has �een demonstrated that prod�ction of IL-�� and 
IL-�� in oesophageal cancer correlated with s�rvival rate 
of patients. The prognosis of patients who had a high level 
of �oth IL-�� and IL-�� was poor. These patients tended 
to show progressive t�mor invasion [����].   
We tested the relationship �etween concentrations 
of ser�m IL-�� or IL-�� and clinical and histopathologi-
cal parameters in the patients with E���. We o�served 
no significant differences in levels of IL-�� �etween       
the stages of E���. However�� as the stage of cancer 
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progressed�� ser�m IL-�� levels tended to increase and 
�ecame statistically significant �etween stage II and IV.
Kawa�ata et al. [�] demonstrated that in gastric 
carcinoma levels of IL-�� have �een shown to �e higher 
in stage II and III compared with stage I and IV of the 
disease. These res�lts are in opposite to o�r st�dy and 
other investigators [��]�� and did not apply to patients 
with other malignant t�mors [7�� ���]. Takahashi et al. 
[��] fo�nd that in advanced gastric cancer amo�nts of 
IL-�� and IL-�� increased and activated the prod�ction 
of hydrogen peroxide and the intracell�lar synthesis 
of IL-�� and IL-� in comparison with early stage of the 
disease. In oesophageal carcinoma�� ser�m IL-�� and 
IL-�� levels increased as the clinical stage progressed�� 
altho�gh there were no significant differences �etween 
them [�]. Based on o�r st�dy�� we s�ggest that IL-�� 
prod�ction can �e ind�ced especially in response to 
the factors related to t�mor development. 
In the presence of IL-�� and IL-�� a�gment Th� 
imm�ne responses�� incl�ding the prod�ction of IFN-γ 
[��� ���� �4]. Kawa�ata et al. [�] o�served the red�ction 
of IFN-γ prod�ction in gastric carcinoma patients and 
s�ggested that it can res�lt in elevation of IL-�� levels 
�y compensatory feed�ack mechanism.
�everal investigators reported that IL-�� plays an 
important role in Th� response and possi�ility in Th� 
response. Another cytokines�� s�ch as IL-���� may affect 
the prod�ction and f�nction of IL-��. This is a specific 
cytokine�� in contrast to IL-���� which enhanced only 
Th� responses [�4].
�ome st�dies report that t�morcellscancontri��teto     
an imm�nos�pressed state in the host. This strategy helps 
the t�mor cells to escape from host — imm�ne s�rveil-
lance [�5�� ���]. It may acco�nt for the fact that in o�r st�dy 
ser�m IL-�� levels were similar in all stages of cancer.
We demonstrated that as the depth of t�mor inva-
sion progressed�� ser�m IL-�� and IL-�� tended to 
increase. We o�served significant differences �etween 
ser�m IL-�� levels in T� vs T� and T� vs T4 depth of 
t�mor invasion. Ts��oi et al. [�] reported that val�es 
of IL-�� and IL-�� were the highest in T� cases. In o�r 
st�dy there were no E��� patients with the T� depth 
of t�mor�� ��t we o�served the highest val�es for IL-�� 
in T4 cases and for IL-�� levels — in T� and T4 cases. 
We have shown statistically significant differences in 
levels of IL-�� �etween N� and N� + N� in regional 
lymph node metastasis.
Nakajima et al. [�7] reported that lymphocyte 
infiltration aro�nd cancero�s lesions is an important 
imm�ne response. When the t�mor remains in the m�-
cosal or s��m�cosal layer�� there is a strong tendency 
for lymphocyte infiltration. Lymphocyte infiltration 
decreased as the depth of invasion progressed. In o�r 
st�dy the val�es of IL-�� and especially IL-�� were high 
in N� + N� cases as a res�lt of the imm�ne response 
per clinical stage of cancer. 
�ome reports s�ggested that IL-�� inhi�its an-
giogenesis�� s�ppresses t�mor growth and enhances 
antit�mor responses. High level of IL-�� in advanced 
cancer can inhi�it proangiogenic factors: VEGF-A�� 
VEGF-� and others [���� ���� ���� ��]. It was recently 
reported that t�mors co�ld co�nterattack imm�ne 
system �y secreting IL-��. The ser�m IL-�� concen-
tration was higher in metastatic cancer patients than 
in patients at initial stages of cancer [��]. Kim et al. 
[��] showed that recom�inant h�man VEGF in gastric 
cancer cells can enhance IL-�� prod�ction and high 
level of IL-�� activated migration of cancer cells. This 
s�ggests that the IL-�� derived from cancer cells is 
involved in the metastatic process.
In concl�sion�� concentrations of ser�m IL-�� and 
IL-�� are significantly higher in E��� patients than in 
the healthy s��jects. Especially in case of IL-�� we 
have o�served relation �etween interle�kin level and 
cancer progression. We hope that IL-�� and IL-�� con-
tent co�ld �e �sed as diagnostic marker in detection 
of E��� development.
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УРОВНИ ИНТЕРЛЕЙКИНА-12 И ИНТЕРЛЕЙКИНА-18 
В СЫВОРОТКЕ КРОВИ БОЛЬНЫХ ПЛОСКОКЛЕТОЧНОЙ 
КАРЦИНОМОЙ ПИЩЕВОДА 
Интерлейкин-12 (И�-12) и интерлейкин-18 (И�-18) и�р��т ���н�� р�л�� � к��е�т�е и���н�����лир���и�� ��кт�р�� �            
п�т��енезе зл�к��е�т�енны�� н����бр�з���ний. Цель: �н�лиз из�енений �р��ней И�-12 и И�-18 � �ы��р�тке кр��и б�л��-      
ны�� пл��к�клет��ны� р�к�� пи�е���� при пр��ре��ир���нии з�б�ле��ния. Материалы и методы: �бр�зцы кр��и бр�ли � 
41 б�л��н��� р�к�� пи�е���� (5 �ен�ин и 36 ����ин, �ре�ний ��зр��т 59 ± 9 лет). У 23 б�л��ны�� � �т��ии II и III пр��ели    
��ир�р�и�е�к�е ���ление �п����ли, 18 б�л��ны� � IV �т��ией з�б�ле��ния пр����или п�лли�ти�н�е ле�ение. ��нтр�л��н�я       
�р�пп� ���т�ял� из 15 з��р��ы�� ��н�р�� (4 �ен�ин и 11 ����ин, �ре�ний ��зр��т 41 ± 6 лет). ��нцентр�ции И�-12 и И�-18   
�пре�еляли и���н��ер�ентны� �ет����. Результаты: �р��ни И�-12 и И�-18 � �ы��р�тке кр��и б�л��ны�� р�к�� пи�е-        
���� зн��ител��н� �ыше, �е� � з��р��ы�� л��ей (p < 0,001). Ур��ен�� И�-12 �ыше � б�л��ны�� � IV �т��ией з�б�ле��ния, �е�         
� б�л��ны�� �� �т��ия�и II и III. Ур��ен�� И�-18 � �ы��р�тке кр��и б�л��ны�� � IV �т��ией з�б�ле��ния �ыше, �е� � б�л��ны��,                 
перене�ши�� ��ир�р�и�е�к�е ��еш�тел���т�� (p < 0,05). Ст�ти�ти�е�ки зн��и�ые р�зли�ия � �р��не И�-18 з��и�ели �т р�зли�-   
ны�� клиник�-п�т�л��и�е�ки�� п�р��етр�� (�т��ии з�б�ле��ния, �п����ле��й ин��зии, н�ли�ия �ет��т�з�� � ли���ти�е�ки�� 
�зл���) (p < 0,05). Выводы: �р��ни И�-12 и И�-18 � �ы��р�тке кр��и � б�л��ны�� р�к�� пи�е���� зн��ител��н� �ыше, �е� �              
з��р��ы�� л��ей-��н�р��. Выя�лен� з��и�и���т�� �е��� ���ер��ние� И�-18 и пр��ре��ир���ние� з�б�ле��ния.    
Ключевые слова: интерлейкин-12, интерлейкин-18, пл��к�клет��ный р�к пи�е����.
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